Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

Abroad (travel likely)RecruitingPHASE1

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Illinois Cancer Center, Chicago, Illinois, United States
Contact: Study coordinator (Karen Sweiss, PharmD) · ksweis2@uic.edu · 312-996-0875

Study leads

Karen Sweiss, PhamD
Principal Investigator
University of Illinois at Chicago

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Birmingham, United States · Phoenix, United States

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Multiple Myeloma · Hematologic Malignancies

Abroad (travel likely)RecruitingPHASE1

Chengdu, China

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma (MM)

Abroad (travel likely)RecruitingPHASE1

Springdale, United States · Jacksonville, United States

Hypofractionation (Radiation) Trial for Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Chicago, United States